ROCHE GLYCART AG
Patent Owner
Stats
- 47 US PATENTS IN FORCE
- 8 US APPLICATIONS PENDING
- Jan 11, 2018 most recent publication
Details
- 47 Issued Patents
- 0 Issued in last 3 years
- 0 Published in last 3 years
- 4,280 Total Citation Count
- Apr 20, 1999 Earliest Filing
- 66 Expired/Abandoned/Withdrawn Patents
Patent Activity in the Last 10 Years
Technologies
Intl Class
Technology
Matters
Rank in Class
Top Patents (by citation)
Upgrade to the Professional Level to View Top Patents for this Owner. Learn More |
Recent Publications
Publication #
Title
Filing Date
Pub Date
Intl Class
2017/0260,265 BISPECIFIC ANTI-VEGF/ANTI-ANG-2 ANTIBODIES AND THEIR USE IN THE TREATMENT OF OCULAR VASCULAR DISEASESMay 23, 17Sep 14, 17[C07K]
2015/0274,845 BISPECIFIC ANTIBODIES SPECIFIC FOR T-CELL ACTIVATING ANTIGENS AND A TUMOR ANTIGEN AND METHODS OF USEMay 05, 14Oct 01, 15[C07K]
2013/0060,011 FC-FREE ANTIBODIES COMPRISING TWO FAB FRAGMENTS AND METHODS OF USEAug 21, 12Mar 07, 13[C12P, C12N, C07K]
Recent Patents
Patent #
Title
Filing Date
Issue Date
Intl Class
9718885 Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicityJul 10, 15Aug 01, 17[C12P, C07K]
9695233 Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseasesJul 11, 13Jul 04, 17[A61K, C07K]
9631023 Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicityMar 24, 16Apr 25, 17[A61K, C12P, C12N, C07K]
9360481 Predictive biomarker for cancer treatment with ADCC-enhanced antibodiesJan 21, 14Jun 07, 16[A61K, G01N, C07K]
Expired/Abandoned/Withdrawn Patents
Patent #
Title
Status
Filing Date
Issue/Pub Date
Intl Class
2017/0174,776 METHOD AND CONSTRUCTS FOR THE pH DEPENDENT PASSAGE OF THE BLOOD-BRAIN-BARRIERAbandonedDec 01, 15Jun 22, 17[C07K]
2016/0264,651 ANTI-TENASCIN-C A2 ANTIBODIES AND METHODS OF USEAbandonedSep 02, 15Sep 15, 16[A61K, C07K]
2016/0166,688 COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH BENDAMUSTINEAbandonedMay 08, 14Jun 16, 16[A61K]
2016/0145,354 BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULESAbandonedAug 25, 15May 26, 16[C07K]
2016/0083,477 Removal of Cancer Cells by Circulating Virus-Specific Cytotoxic T-Cells Using Cancer Cell Targeted MHC Class 1 Compromising Multi-Function ProteinsAbandonedMay 28, 15Mar 24, 16[C12N, C07K]
2016/0075,795 Antibodies to Carcinoembryonic Antigen (CEA), Methods of Making Same, and Uses ThereofAbandonedMay 26, 15Mar 17, 16[C07K]
2016/0017,050 COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH AN ANTI-VEGFAbandonedSep 17, 15Jan 21, 16[A61K, C07K]
2016/0000,911 COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH INCREASED ANTIBODY DEPENDENT CELLULAR CYTOTOXITY (ADCC)AbandonedJun 05, 14Jan 07, 16[A61K]
2016/0000,912 COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A PROTEASOME INHIBITORAbandonedJun 16, 14Jan 07, 16[A61K]
2015/0344,584 Modified Antigen Binding Molecules With Altered Cell Signaling ActivityAbandonedDec 19, 14Dec 03, 15[C07K]
2015/0274,834 COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH FLUDARABINE AND/OR MITOXANTRONEAbandonedJun 15, 15Oct 01, 15[A61K, C07K]
2015/0265,703 COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH A mTOR INHIBITORAbandonedJun 04, 15Sep 24, 15[A61K, A61N]
2015/0079,073 COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH FLUDARABINE AND/OR MITOXANTRONEAbandonedApr 11, 14Mar 19, 15[A61K]
2015/0071,911 COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH A mTOR INHIBITORAbandonedMar 31, 14Mar 12, 15[A61K, C07K]
2014/0322,200 COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH AN ANTI-VEGF ANTIBODYAbandonedNov 27, 13Oct 30, 14[A61K, A61N]
Top Inventors for This Owner
Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More |
We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!
We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.